أعرض في EDS

One-year safety, immunogenicity, and survival results from a phase III study comparing SB3 (a proposed trastuzumab biosimilar) and originator trastuzumab in HER2-positive early breast cancer treated with neoadjuvant-adjuvant treatment

التفاصيل البيبلوغرافية
العنوان:	One-year safety, immunogenicity, and survival results from a phase III study comparing SB3 (a proposed trastuzumab biosimilar) and originator trastuzumab in HER2-positive early breast cancer treated with neoadjuvant-adjuvant treatment
المؤلفون:	Vladimir Semiglazov, Maximino De Guzman Bello, Xavier Pivot, S-A. Im, Marek Z. Wojtukiewicz, Jae Yun Lim, Yaroslav Shparyk, L. Younju, Zbigniew Nowecki, Sanjoy Chatterjee, Tomasz Sarosiek, J-H. Ahn, I. Bondarenko, Yuriy Vinnyk, Ekaterina Trishkina, Vladimir Moiseyenko, M. Dvorkin
المصدر:	ResearcherID
مصطلحات موضوعية:	Oncology, medicine.medical_specialty, 030219 obstetrics & reproductive medicine, business.industry, medicine.medical_treatment, Immunogenicity, Biosimilar, Hematology, 03 medical and health sciences, 0302 clinical medicine, Trastuzumab, 030220 oncology & carcinogenesis, Internal medicine, medicine, business, Adjuvant, Early breast cancer, medicine.drug
الوصول الحر:	https://explore.openaire.eu/search/publication?articleId=doi_dedup___::32710c319c83b36d3955dc96f3e0c284Test http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcAuth=ORCID&SrcApp=OrcidOrg&DestLinkType=FullRecord&DestApp=WOS_CPL&KeyUT=WOS:000411324000081&KeyUID=WOS:000411324000081Test
حقوق:	OPEN
رقم الانضمام:	edsair.doi.dedup.....32710c319c83b36d3955dc96f3e0c284
قاعدة البيانات:	OpenAIRE

الوصف
الوصف غير متاح.